FDA Breakthrough granted for Roche’s Gazyva

PharmaTimes | September 19, 2019

FDA Breakthrough granted for Roche’s Gazyva
Roche has announced that Gazyva (obinutuzumab) has received US Food and Drug Administration (FDA) Breakthrough Therapy Designation (BTD) for adults with lupus nephritis. The designation was based on the Phase II NOBILITY study, in which the drug in combination with standard of care (mycophenolate mofetil or mycophenolic acid and corticosteroids), demonstrated enhanced efficacy compared to placebo and standard of care alone in achieving complete renal response at one year. The trial also met its secondary endpoints, showing improved overall renal responses (complete and partial renal response) and serologic markers of disease activity as compared to placebo. Gazyva is an engineered monoclonal antibody designed to attach to CD20, a protein found only on certain types of B-cells. It is thought to work by attacking targeted cells both directly and together with the body's immune system. Sandra Horning, Roche’s chief medical officer and head of global product development, reminded that “new treatment options are needed for lupus nephritis”, and explained that the company is “committed to developing Gazyva as a potential new therapy for lupus nephritis and plan to begin enrolling patients in a phase III trial next year.”

Spotlight

If you want some insights into where the content marketing industry may be headed, it might just help to take a look at where it’s been. As we pointed out when CMI shared its History of Content Marketing infographic in 2012, brands have been telling their stories to audiences for hundreds of years. Not to mention that storytelling itself is one of the oldest forms of communication. Benjamin Franklin first publishes the yearly Poor Richard’s Almanack. The goal is to promote his printing business.

Related News

Amarin Announces Plans to Maximize Blockbuster Potential of VASCEPA® in Europe

Amarin spurns | August 05, 2020

Amarin's wild 2020 ride continues. Tuesday, the company said COVID-19 took a bite out of second quarter earnings, and it unveiled plans to launch its fish-oil derivative drug Vascepa in Europe without help from a bigger marketing partner. And that's on top of prepping for federal court this fall, where it will try to salvage Vascepa's key patents. Amarin positioned its European plans as a positive: It did receive multiple proposals from potential partners. But the significant sales opportunity for Vascepa in the E.U. means retaining product rights is the company's best move, executives said during an earnings call with analysts. While Vascepa is still awaiting approval in Europe, expected in early 2021, Amarin has already hired a commercial head, Karim Mikhail, who joined from his own commercial consultancy founded in 2018. Before that, though, he spent 22 years in a variety of roles at Merck, including as global leader for its lipid franchise and chief marketing officer for the EMEA region.

Read More

Tetra Bio-Pharma Gets Orphan Drug Status For CBD Drug

Greenmarketreport | April 22, 2020

Tetra Bio-Pharma Inc. (OTCQB:TBPMF) announced its Orphan Drug development strategy and provided a management update. The company said it is focusing on generating intellectual property including use, manufacturing, and innovative molecule protection. Tetra said it received a U.S. Food and Drug Administration (FDA) Orphan Drug Designation for secondary cannabidiol (CBD) formulation of its cannabinoid topical drug PPP004 in the treatment of epidermolysis bullosa. “Each ODD application is driven by scientific data generated by Tetra’s research and development department and in line with a commercialization strategy. Tetra is positioning itself as a world leader in cannabinoid drug development and increasing its ODD portfolio provides opportunities that will allow us to generate value for shareholders. Over the coming weeks, Tetra shall expand on its commercial ophthalmic and topical drug programs,” said Dr. Chamberland CEO & CRO, Tetra Bio-Pharma Inc.

Read More

CVS head of specialty pharmacy sees future of healthcare at home after Covid-19

Medcity news | May 26, 2020

Mail-order prescriptions are nothing new, but pharmacists have turned to a number of other tools to help patients access their prescriptions during the Covid-19 pandemic. The head of CVS Health’s specialty pharmacy strategy, Prem Shah, said he expects to see more patients continue receive healthcare at home after the pandemic ends. Though CVS Health had been building up its arsenal of digital tools before the Covid-19 pandemic, stay-at-home orders forced the pharmacy giant to lean more on them. The company has seen a surge in the use of its support services since the beginning of March.

Read More

Spotlight

If you want some insights into where the content marketing industry may be headed, it might just help to take a look at where it’s been. As we pointed out when CMI shared its History of Content Marketing infographic in 2012, brands have been telling their stories to audiences for hundreds of years. Not to mention that storytelling itself is one of the oldest forms of communication. Benjamin Franklin first publishes the yearly Poor Richard’s Almanack. The goal is to promote his printing business.